Shire's SHP607 misses retinopathy endpoint

Shire plc (LSE:SHP; NASDAQ:SHPG) said SHP607 missed the primary endpoint in a Phase II study. The compound failed

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE